Investing.com-- Eisai Co. ’s (TYO:4523) Alzheimer’s drug Leqembi is showing early signs of a long-awaited sales inflection, ...
France was once a pioneer of Alzheimer's care, but as the number of sufferers continues to rise and budgets are cut, the ...
Alzheimer’s Disease (AD), the most common cause of dementia, is one of the most pressing health challenges of our time. The ...
PARIS: After decades of unsuccessful research, two new drugs and a pioneering blood test have recently given Alzheimer's ...
The FDA has approved a once-weekly autoinjector version of Eisai’s Leqembi, as the company seeks to grow the drug’s uptake.
SaveHealth reports on advancements in dementia medications, highlighting new treatments that modify disease progression and ...
After decades of unsuccessful research, two new drugs and a pioneering blood test have recently given Alzheimer's patients ...
Health officials scour research journals looking for studies that could really make a difference. Here is the scoop on Wegovy ...
After decades of setbacks, new Alzheimer’s drugs and a groundbreaking blood test offer cautious hope; though questions about ...
STOCKHOLM, Aug. 25, 2025 /PRNewswire/ --BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai announced today that the launch of Leqembi in the EU started in Austria on August 25, 2025, and ...
LEQEMBI IQLIK is the first and only anti-amyloid treatment to offer an at-home injection to help patients and care partners continue to treat this progressive, relentless disease after initial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback